Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Innoviva, Inc. (INVA : NSDQ)
 
 • Company Description   
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $16.29 Daily Weekly Monthly
20 Day Moving Average: 1,009,527 shares
Shares Outstanding: 69.57 (millions)
Market Capitalization: $1,133.22 (millions)
Beta: 0.50
52 Week High: $20.71
52 Week Low: $12.14
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.64% 0.04%
12 Week -15.94% -5.53%
Year To Date -5.57% 15.37%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1350 OLD BAYSHORE HIGHWAY SUITE 400
-
BURLINGAME,CA 94010
USA
ph: 650-238-9600
fax: 650-827-8690
investor.relations@inva.com http://www.inva.com
 
 • General Corporate Information   
Officers
Pavel Raifeld - Chief Executive Officer
George Bickerstaff - Chairman
Marianne Zhen - Chief Accounting Officer
Odysseas Kostas - Director
Mark DiPaolo - Director

Peer Information
Innoviva, Inc. (AGN.)
Innoviva, Inc. (ABBV)
Innoviva, Inc. (NVO)
Innoviva, Inc. (LLY)
Innoviva, Inc. (RHHBY)
Innoviva, Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 45781M101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
Share - Related Items
Shares Outstanding: 69.57
Most Recent Split Date: (:1)
Beta: 0.50
Market Capitalization: $1,133.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.58 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.80 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 9.05
Trailing 12 Months: 5.88
PEG Ratio: -
Price Ratios
Price/Book: 2.05
Price/Cash Flow: 3.51
Price / Sales: 2.86
EPS Growth
vs. Year Ago Period: -50.00%
vs. Previous Quarter: -23.64%
Sales Growth
vs. Year Ago Period: 5.31%
vs. Previous Quarter: -16.36%
ROE
03/31/22 - 49.31
12/31/21 - 56.88
09/30/21 - 56.51
ROA
03/31/22 - 26.10
12/31/21 - 32.49
09/30/21 - 32.88
Current Ratio
03/31/22 - 2.91
12/31/21 - 54.02
09/30/21 - 75.82
Quick Ratio
03/31/22 - 2.91
12/31/21 - 54.02
09/30/21 - 75.82
Operating Margin
03/31/22 - 61.07
12/31/21 - 76.50
09/30/21 - 82.58
Net Margin
03/31/22 - 47.30
12/31/21 - 67.84
09/30/21 - 82.58
Pre-Tax Margin
03/31/22 - 90.96
12/31/21 - 113.63
09/30/21 - 127.99
Book Value
03/31/22 - 7.94
12/31/21 - 7.56
09/30/21 - 7.08
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.80
12/31/21 - 0.75
09/30/21 - 0.80
Debt-to-Capital
03/31/22 - 44.50
12/31/21 - 42.87
09/30/21 - 44.37
 

Powered by Zacks Investment Research ©